Randomized, Controlled Trial of an Injectable Biologic and U0279 [acitretin] as Combination Therapy for Severe Plaque-Type Psoriasis.

Trial Profile

Randomized, Controlled Trial of an Injectable Biologic and U0279 [acitretin] as Combination Therapy for Severe Plaque-Type Psoriasis.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Acitretin (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Stiefel Laboratories
  • Most Recent Events

    • 23 Jun 2011 Actual initiation date changed from Feb 2009 to Oct 2009, GlaxoSmithKline added in the association as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top